Growth hormone treatment and left ventricular dimensions in Turner syndrome

J Pediatr. 2007 Jun;150(6):587-91. doi: 10.1016/j.jpeds.2007.02.009.

Abstract

Objective: To determine whether cardiac dimensions were different in girls with Turner syndrome (TS) who received growth hormone (GH) compared with those who did not receive GH.

Study design: This retrospective, cross-sectional study analyzed echocardiograms in 86 females with TS divided into GH-treated (n = 67) and untreated (n = 19) groups. The subjects all participated in the National Institutes of Health protocol between 2001 and 2006.

Results: The average age was 16.2 years (range, 10 to 25 years), and average duration of GH treatment was 4.4 years (range, 1 to 14 years). The GH-treated group was taller by approximately 7 cm (P = .004), but cardiac dimensions normalized to body surface area (BSA), including septal and posterior wall thickness and left ventricular (LV) mass and internal diameters, did not differ significantly between the 2 groups. The fractional shortening index was similar in the 2 groups. Multiple regression analyses indicated that BSA, but not duration of GH treatment, predicted LV dimensions in girls with TS.

Conclusions: GH treatment of girls with TS increases stature but does not disproportionately affect cardiac dimensions.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Adolescent
  • Adult
  • Body Surface Area
  • Child
  • Cross-Sectional Studies
  • Echocardiography, Doppler
  • Female
  • Growth Hormone / therapeutic use*
  • Heart / drug effects*
  • Heart Ventricles / diagnostic imaging
  • Heart Ventricles / drug effects*
  • Human Growth Hormone / pharmacology*
  • Human Growth Hormone / therapeutic use
  • Humans
  • Regression Analysis
  • Turner Syndrome / diagnostic imaging*
  • Turner Syndrome / drug therapy*
  • Turner Syndrome / physiopathology

Substances

  • Human Growth Hormone
  • Growth Hormone